2016
DOI: 10.1371/journal.pntd.0004292
|View full text |Cite
|
Sign up to set email alerts
|

A Recombinant Positive Control for Serology Diagnostic Tests Supporting Elimination of Onchocerca volvulus

Abstract: BackgroundSerological assays for human IgG4 to the Onchocerca volvulus antigen Ov16 have been used to confirm elimination of onchocerciasis in much of the Americas and parts of Africa. A standardized source of positive control antibody (human anti-Ov16 IgG4) will ensure the quality of surveillance data using these tests.Methodology/Principal FindingsA recombinant human IgG4 antibody to Ov16 was identified by screening against a synthetic human Fab phage display library and converted into human IgG4. This antib… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
28
0

Year Published

2016
2016
2019
2019

Publication Types

Select...
4
2
1

Relationship

3
4

Authors

Journals

citations
Cited by 27 publications
(29 citation statements)
references
References 29 publications
1
28
0
Order By: Relevance
“…The studies were performed by staff members of the Togo National Program for Onchocerciasis (PNLO) and the Laboratory for Onchocerciasis Research (LRO). For each study, the staff received a two-day training course for performing study procedures including appropriate consent, data management, and utilizing the dried-down recombinant positive control [ 30 ]. In addition, a research team member was present for the first several hundred study participants to monitor test use and to provide ongoing support.…”
Section: Methodsmentioning
confidence: 99%
See 2 more Smart Citations
“…The studies were performed by staff members of the Togo National Program for Onchocerciasis (PNLO) and the Laboratory for Onchocerciasis Research (LRO). For each study, the staff received a two-day training course for performing study procedures including appropriate consent, data management, and utilizing the dried-down recombinant positive control [ 30 ]. In addition, a research team member was present for the first several hundred study participants to monitor test use and to provide ongoing support.…”
Section: Methodsmentioning
confidence: 99%
“…The solution was mixed gently before use in ELISA. For Ov16 ELISA, 100 μl of 5 μg/ml Ov16 antigen diluted in PBS, pH 7.4 (Sigma Chemical Company, St. Louis, MO, USA) was added to plate wells, Immulon 2HB (Fisher Scientific, Pittsburgh, PA, USA) [ 30 ]. For the glutathione-S-transferase (GST) ELISA, 100 μl of 2 μg/ml GST protein (Thermo Fisher, Waltham, MA, USA) was added to plate wells.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…Currently, there is no standardized commercially available Ov16 ELISA so variations in protocols and procedures exist across labs. [ 15 , 16 ] In 2014, a field deployable, rapid diagnostic tool that could be more easily integrated into current onchocerciases surveillance programs in endemic countries was developed and made commercially available (SD BIOLINE Onchocerciasis IgG4 rapid test, referred to here as Ov16 rapid test). [ 17 , 18 ] Performance of the Ov16 rapid test continues to be evaluated in the field and current global research priorities focus on operational and implementation research to demonstrate utility and increase access of the Ov16 rapid test, particularly in low prevalence settings which have undergone multiple rounds of MDA.…”
Section: Introductionmentioning
confidence: 99%
“…Traditionally, diagnosis of onchocerciasis relied on positivity for microfilariae from skin snips [6], PCR for the interspersed O-150 repeat [7] or IgG4 responses to Ov16 [8-12]. Recent modeling studies indicate the usefulness of Ov16 seropositivity in conjunction with skin snip results for MDA and surveillance programs for onchocerciasis [13].…”
Section: Introductionmentioning
confidence: 99%